Preparing for the Next MHRA & EMA Inspection Cycle

Regulatory inspections remain one of the most important aspects of pharmaceutical quality assurance. As the pharmaceutical industry continues to evolve through digital transformation, global supply chain complexity, and increasing regulatory expectations, organisations must ensure they are consistently inspection-ready.

Both the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) and the European Medicines Agency (EMA) continue to strengthen their focus on Good Manufacturing Practice (GMP), data integrity, quality risk management, and operational oversight. For professionals working in pharmaceutical quality assurance, regulatory affairs, manufacturing, and compliance, preparing for the next inspection cycle is no longer a reactive exercise; it is an ongoing operational requirement.

Inspection readiness today means more than simply having documentation available. Regulators increasingly expect companies to demonstrate mature quality systems, effective governance, strong data management practices, and a proactive quality culture throughout the organisation.

Understanding the Current Inspection Landscape

MHRA and EMA inspections are becoming increasingly risk-based and data-driven. Regulatory authorities are placing greater emphasis on identifying systemic weaknesses rather than isolated documentation errors.

The MHRA has confirmed that many GMP and GCP inspections now follow risk-based compliance programmes, allowing inspectors to focus on areas with the highest potential patient or product risk.

Similarly, the EMA continues to harmonise inspection procedures across EU member states through coordinated GMP inspection guidance and inspection information-sharing frameworks.

For pharmaceutical manufacturers, this means inspectors are increasingly focused on:

• Data integrity controls
• Quality management system effectiveness
• Supplier and third-party oversight
• Contamination control strategies
• Computer system validation
• Risk management processes
• Training effectiveness
• CAPA effectiveness and closure timelines

Companies should also be aware that temporary regulatory flexibilities introduced during the COVID-19 period are being phased out, resulting in a return to more standardised inspection expectations.

Building a Continuous State of Inspection Readiness

One of the most common mistakes organisations make is treating inspection preparation as a short-term project shortly before an audit or regulatory visit. In reality, regulators expect sites to maintain a continuous state of GMP compliance.

A strong inspection readiness strategy should include routine internal reviews, mock inspections, and ongoing quality system monitoring.

Strengthen Documentation and Data Integrity

Documentation remains one of the most heavily scrutinised areas during inspections. Inspectors expect records to be complete, contemporaneous, attributable, accurate, and secure throughout the data lifecycle.

Data integrity deficiencies continue to be a significant focus during MHRA inspections, particularly in relation to audit trails, shared access credentials, unofficial records, and undocumented data changes.

To improve readiness, organisations should:

• Conduct regular data integrity audits
• Review user access controls
• Verify audit trail functionality
• Ensure electronic systems are appropriately validated
• Reinforce ALCOA+ principles across all departments
• Eliminate unofficial or temporary record-keeping practices

Training staff to understand both the technical and behavioural aspects of data integrity is equally important.

Review Quality Risk Management Processes

Regulators increasingly expect companies to demonstrate the use of effective Quality Risk Management (QRM) principles throughout operations.

Risk assessments should not simply exist as completed templates; inspectors want evidence that risks are actively reviewed, mitigated, and linked to operational decision-making.

Organisations should review:

• Deviation trending processes
• CAPA effectiveness monitoring
• Supplier qualification programmes
• Environmental monitoring trends
• Change control systems
• Escalation procedures for critical events

A mature QRM system helps demonstrate that quality oversight is proactive rather than reactive.

Prepare Staff for Inspection Interaction

Inspection readiness is not limited to QA departments. Inspectors may speak with personnel across manufacturing, warehousing, QC laboratories, engineering, validation, and supply chain functions.

Employees should feel confident:

• Explaining their roles and responsibilities
• Describing relevant procedures
• Demonstrating GMP awareness
• Escalating issues appropriately
• Answering questions clearly and honestly

Mock inspections and interview preparation exercises can help reduce anxiety and improve consistency during inspections.

Training records should also demonstrate that personnel are appropriately qualified for their responsibilities, an area regulators continue to examine closely.

Focus on Digital Systems and Computer Validation

As pharmaceutical operations become increasingly digital, inspectors are placing greater emphasis on computer system validation and electronic quality management systems.

Recent regulatory discussions around revisions to EU GMP Annex 11 reflect the industry’s growing reliance on digital technologies and automated systems.

Companies should ensure:

• Computer systems are validated and maintained
• Cybersecurity controls are documented
• Backup and disaster recovery procedures are tested
• Electronic signatures comply with regulatory requirements
• Change management processes cover digital infrastructure

Inspectors are increasingly interested in how organisations manage both operational technology and data governance risks.

Conduct Effective Mock Inspections

Mock inspections remain one of the most effective ways to identify weaknesses before regulators do.

A successful mock inspection should simulate real inspection conditions as closely as possible, including:

• Document retrieval exercises
• Facility walkthroughs
• Staff interviews
• Deviation and CAPA reviews
• Data integrity assessments
• System traceability checks

Cross-functional participation is essential to ensure all departments understand their responsibilities during inspections.

The Importance of Quality Culture

Ultimately, regulators are assessing more than compliance documentation; they are evaluating the organisation’s overall quality culture.

A strong quality culture is reflected through:

• Transparent communication
• Timely issue escalation
• Continuous improvement initiatives
• Management engagement
• Employee accountability
• Patient-focused decision-making

Companies that treat inspections as opportunities to demonstrate operational maturity rather than regulatory obstacles are often better positioned for long-term compliance success.

Final Thoughts

Preparing for the next MHRA and EMA inspection cycle requires more than a last-minute review of SOPs and records. As inspection expectations continue to evolve, pharmaceutical companies must build resilient quality systems supported by strong governance, effective risk management, and a culture of continuous compliance.

For quality professionals, staying inspection-ready means maintaining visibility across operations, understanding evolving regulatory priorities, and ensuring that quality is embedded into every stage of pharmaceutical manufacturing and supply chain management.

The organisations that succeed during inspections are typically those that prioritise preparation every day, not only when regulators are scheduled to arrive.